The governance of Artificial Intelligence as a Medical Device (AIaMD) presents unique challenges related to algorithmic adaptivity, transparency, and assurance of continuous safety. The UK’s regulatory approach to this domain is strategically defined by a commitment to agility and innovation, leveraging existing sectoral regulators rather than relying on monolithic, preemptive legislation.